TKNO vs. CODX, AXDX, DMTK, ACHV, VNRX, ABIO, ICCC, AWH, OCX, and CDIO
Should you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include Co-Diagnostics (CODX), Accelerate Diagnostics (AXDX), DermTech (DMTK), Achieve Life Sciences (ACHV), VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), and Cardio Diagnostics (CDIO). These companies are all part of the "medical" sector.
Alpha Teknova (NASDAQ:TKNO) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 15.2% of Alpha Teknova shares are held by insiders. Comparatively, 2.4% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Co-Diagnostics received 266 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 33.33% of users gave Alpha Teknova an outperform vote.
Co-Diagnostics has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500.
Alpha Teknova has a net margin of -97.85% compared to Co-Diagnostics' net margin of -582.36%. Alpha Teknova's return on equity of -38.24% beat Co-Diagnostics' return on equity.
In the previous week, Alpha Teknova and Alpha Teknova both had 3 articles in the media. Alpha Teknova's average media sentiment score of 1.60 beat Co-Diagnostics' score of 1.19 indicating that Alpha Teknova is being referred to more favorably in the media.
Alpha Teknova presently has a consensus target price of $15.00, suggesting a potential upside of 752.27%. Co-Diagnostics has a consensus target price of $2.00, suggesting a potential upside of 90.48%. Given Alpha Teknova's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Teknova is more favorable than Co-Diagnostics.
Summary
Alpha Teknova beats Co-Diagnostics on 11 of the 17 factors compared between the two stocks.
Get Alpha Teknova News Delivered to You Automatically
Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Teknova Competitors List
Related Companies and Tools
